The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice.
about
Update on Guillain-Barré syndromeImbalance in fatty-acid-chain length of gangliosides triggers Alzheimer amyloid deposition in the precuneusInhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis.An update on pathobiologic roles of anti-glycan antibodies in Guillain-Barré syndrome.Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome.Complex of GM1- and GD1a-like lipo-oligosaccharide mimics GM1b, inducing anti-GM1b antibodies.Anti-Ganglioside Antibodies Induce Nodal and Axonal Injury via Fcγ Receptor-Mediated Inflammation.Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies.Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis.Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.Guillain-Barré syndrome: update on immunobiology and treatment.Sphingolipid topology and the dynamic organization and function of membrane proteins.Antibodies against ganglioside complexes in Guillain-Barré syndrome and related disorders.Immunotherapy of multifocal motor neuropathy.The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.The translation of the pathological findings described in humans to experimental models of acute motor axonal neuropathy.Recent developments and future directions in Guillain-Barré syndrome.Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin.C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy.Guillain-Barré syndrome: a century of progress.Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model.Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination.Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation.Passive transfer of IgG anti-GM1 antibodies impairs peripheral nerve repair.Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays.Acute motor axonal neuropathy and multifocal motor neuropathy: more in common than not.Neuronal endocytosis of anti-ganglioside antibodies: implications for Guillain-Barré syndrome.An open label clinical trial of complement inhibition in multifocal motor neuropathy.Differential binding patterns of anti-sulfatide antibodies to glial membranes
P2860
Q28293098-9136E9E3-9768-4F51-B026-13D06FB7F466Q28544853-E3E5A57C-668F-43BD-9A36-657C75E241F8Q33899405-3D737F21-173B-4846-B722-90482F864BAEQ34167468-2C97F89D-9614-4CC7-A0AF-E05FF85AA717Q35072720-71112F2C-2283-4C2D-9BE6-1F5216EBF162Q35389058-EF83E08D-B08E-490C-80FB-E2D770B7D0CAQ35547885-21775224-DD69-4A9F-9E18-33B63012F905Q35713309-C69E67E8-7F7A-4B33-A927-354B4061DEBDQ35780245-7C1876EA-F119-4060-86B0-E275F3843392Q36174702-03A7F2A9-227E-4FD3-9D32-3BDDB1F253FBQ36967702-EA0AB071-4291-4873-89A6-67E1C7C008A6Q37494674-31BB2FC0-A94A-4781-8865-2B53133C0295Q37535345-A4DDF593-382B-4347-B0FE-59D035F83A85Q37600859-C7715105-ED5C-4A57-AE5A-A1F072382E11Q37616697-F03D126C-F3BF-4B45-8A52-7AA0ED1C00D1Q37826777-FC96E377-6D13-47AD-9F5E-DF1345C487B6Q37836898-26BB5B68-21A2-4A98-8BE0-91764742D74CQ37862736-5FA03318-C11E-4975-86FF-42ED5567DD7EQ38070878-E128A600-F58D-41D0-A12E-F46384E24FA2Q38070887-38CB66A2-1415-47E0-B4F7-E3EC95F375A5Q38605062-F1994A27-1CB5-4A2D-9344-D96BE732DADAQ38748904-6488607B-C24E-4C61-A0C2-422F03D79569Q39011456-50F6A5D3-4271-4BB3-B871-FFD0344A4EAFQ39227455-2DD28E95-48CF-49B9-B148-8342D3DF00BFQ39808275-A3EE189C-296E-4757-A6E0-24E96360BF4FQ40281429-DF9E99F7-813B-43AB-9841-5C13870E975CQ40560617-A2221E7D-8189-4C51-AA46-2A9B82D1898CQ42600854-973D8DB3-2036-475D-8714-1D410FF5BFC4Q43120650-29A9CED0-BDB5-42C3-B0AC-0EC6EFB24C06Q45136336-5CD7AF76-54CA-4684-B911-3C6C634E95C9Q48710281-1743F5D6-AC25-4B31-97C4-6ABFF287A3BFQ53239243-F5B4C563-5152-45D6-B25D-F12F99915980Q57464812-40E38DF3-82B4-4AA3-AFCA-38B1749FCD6B
P2860
The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The neuropathic potential of a ...... lycolipid environment in mice.
@en
The neuropathic potential of a ...... lycolipid environment in mice.
@nl
type
label
The neuropathic potential of a ...... lycolipid environment in mice.
@en
The neuropathic potential of a ...... lycolipid environment in mice.
@nl
prefLabel
The neuropathic potential of a ...... lycolipid environment in mice.
@en
The neuropathic potential of a ...... lycolipid environment in mice.
@nl
P2093
P2860
P50
P921
P356
P1476
The neuropathic potential of a ...... glycolipid environment in mice
@en
P2093
Alistair Easton
Colin O'Leary
Femke M P Zitman
Hugh J Willison
Jaap J Plomp
Jennifer Roxburgh
Kathryn M Brennan
Kay N Greenshields
Keiko Furukawa
Koichi Furukawa
P2860
P304
P356
10.1172/JCI37338
P407
P577
2009-02-16T00:00:00Z